Acetylsalicylic Acid + Apixaban Interaction
Majorinteraction on record
Description
Antiplatelet agent that increases bleeding risk when coadministered with apixaban. Concomitant use increased major bleeding risk from 1.8% to 3.4% per year.
Mechanism
Additive anticoagulant/antiplatelet effects
Source: NLP:apixaban